{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:27:52Z","timestamp":1778138872430,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.tranon.2020.100864","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:25:31Z","timestamp":1600388731000},"page":"100864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites"],"prefix":"10.1016","volume":"13","author":[{"given":"Huzheng","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenke","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenkang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2020.100864_bb0005","first-page":"313","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"70","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.tranon.2020.100864_bb0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/hep.20871","article-title":"Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era","volume":"42","author":"Ripoll","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2020.100864_bb0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/bjs.8753","article-title":"Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis","volume":"99","author":"Boleslawski","year":"2012","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.tranon.2020.100864_bb0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/apt.12427","article-title":"Determinants of longterm outcome in severe alcoholic hepatitis","volume":"38","author":"Potts","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2020.100864_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2020.100864_bb0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2020.100864_bb0035","first-page":"514","article-title":"Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients","volume":"88","author":"Salerno","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tranon.2020.100864_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","author":"EASL","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2020.100864_bb0045","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2020.100864_bb0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.12968\/ijpn.2015.21.8.372","article-title":"Patient experience of non-malignant ascites and its treatment: a qualitative study","volume":"21","author":"Day","year":"2015","journal-title":"Int. J. Palliat. Nurs."},{"key":"10.1016\/j.tranon.2020.100864_bb0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2020.100864_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Christophe","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2020.100864_bb0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S2468-1253(19)30090-1","article-title":"Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial","volume":"4","author":"Yong","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.tranon.2020.100864_bb0070","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/gutjnl-2018-317057","article-title":"Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study","volume":"68","author":"Yong","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.tranon.2020.100864_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.20364","article-title":"Randomized controlled study of TIPS vs. paracentesis plus albumin in cirrhosis with severe ascites","volume":"40","author":"Salerno","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2020.100864_bb0080","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.dld.2014.04.009","article-title":"Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study","volume":"46","author":"Adriano","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.tranon.2020.100864_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2020.100864_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2010.06.029","article-title":"Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis","volume":"54","author":"Han","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2020.100864_bb0095","first-page":"1089","article-title":"TIPS for refractory ascites: a single-centre experience","volume":"44","author":"Thalheimer","year":"2009","journal-title":"Gastroenterol."},{"key":"10.1016\/j.tranon.2020.100864_bb0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41395-018-0185-6","article-title":"Refractory ascites in liver cirrhosis","volume":"114","author":"Danielle","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tranon.2020.100864_bb0105","first-page":"349","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2020.100864_bb0110","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2020.100864_bb0115","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00270-017-1655-8","article-title":"Transjugular intrahepatic portosystemic shunt for portal hypertension in hepatocellular carcinoma with portal vein tumor thrombus","volume":"40","author":"Bin","year":"2017","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.tranon.2020.100864_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","article-title":"A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma","volume":"25","author":"Lipika","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100864_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/annonc\/mds225","article-title":"Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Verslype","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2020.100864_bb0130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/apt.12994","article-title":"Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma","volume":"41","author":"Bettinger","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2020.100864_bb0135","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2214\/ajr.182.5.1821301","article-title":"Stent-graft for TIPS in a hepatocellular carcinoma patient with main portal vein invasion","volume":"182","author":"Hur","year":"2004","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.tranon.2020.100864_bb0140","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.12998\/wjcc.v7.i13.1599","article-title":"Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma","volume":"7","author":"Luo","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.tranon.2020.100864_bb0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00270-004-0241-z","article-title":"Transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of venous symptomatic chronic portal thrombosis in non-cirrhotic patients","volume":"27","author":"Bilbao","year":"2004","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.tranon.2020.100864_bb0150","first-page":"232","article-title":"TIPS is not associated with a higher risk of developing hcc in cirrhotic patients: a systematic review and meta-analysis","volume":"7","author":"Bin","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.tranon.2020.100864_bb0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/hepr.12162","article-title":"Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis","volume":"44","author":"Lei","year":"2014","journal-title":"Hepatol. Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:39:22Z","timestamp":1761835162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320303569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1936523320303569"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100864","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100864"}}